跳至主要内容
临床试验/NCT03414307
NCT03414307撤回不适用

ROSA Stereotactic Robot-assisted Intracerebral Hemorrhage Clot Evacuation

Zimmer Biomet2 个研究点 分布在 1 个国家开始时间: 2020年9月30日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
Zimmer Biomet
试验地点
2
主要终点
Hematoma volume reduction

研究概览

简要总结

Non-traumatic intracerebral hemorrhage (ICH) affects approximately 100,000 Americans yearly. Up to 30-50% of ICH is fatal, and those patients who survive are often left with significant neurologic dysfunction. In the past, medical management (e.g., control of hypertension, reversal of antiplatelet or anticoagulants) had been the most effective treatment for these patients, given the morbidity and mortality associated with open surgical treatment for evacuation of ICH. However, recent trials have demonstrated that minimally invasive stereotactic neurosurgical procedures to evacuate ICH are safe and result in improved outcomes for these patients.

Initial attempts to evaluate the efficacy of surgical evacuation of ICH found no significant difference between medical management and standard craniotomy for surgical evacuation. Indeed, open surgery was often discouraged for these patients due to the significant morbidity and mortality associated with the surgical procedure itself. However, research has demonstrated that minimally invasive, image guided stereotactic frame-based and frameless methods are effective and safe for the placement of catheters for clot aspiration and fibrinolytic therapy of ICH in the basal ganglia and other deep seated regions. Larger randomized controlled trials have demonstrated that these minimally invasive approaches also offer clinical benefit for these patients.

详细描述

The introduction of the ROSA stereotactic robot offers an image guided stereotactic approach with greater precision and accuracy than traditional frame-based and frameless methods. While the ROSA has never been used for the placement of intra-hemorrhage catheters, prior applications such as brain biopsies and abscess drainage represent similar surgical procedures which require the same planning, precision, and surgical technique. At the very least, ROSA offers an accurate image guided approach to deep lesions that should be comparable to competitive image guided platforms. At best, ROSA offers superior trajectory planning software, greater ease in planning multiple trajectories to large, irregular clots, and the potential for robot aided navigation into and out of the hematoma which is the greatest source of human error in these cases. For instance, the procedure often requires advancement of a larger aspiration catheter, slow aspiration as the catheter is withdrawn, and then re-advancement of a smaller catheter into the hematoma, which is left in place. The ability to advance and remove catheters in a fixed trajectory with robotic assistance may represent the greatest advantage of ROSA.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-85
  • Head CT demonstrates an acute, spontaneous, supratentorial, primary ICH
  • ICH volume ≥30 cc
  • Surgery initiated within 48 hours of hospital admission

排除标准

  • Pregnancy at the time of surgery
  • Underlying vascular lesion defined as causative source of ICH
  • Irreversible coagulopathy
  • Profound neurological deficit defined as fixed/dilated pupils, bilateral extensor motor posturing
  • Infratentorial or brainstem ICH
  • Known life expectancy <6 months

结局指标

主要结局

Hematoma volume reduction

时间窗: Day 1 to Day 4 post operative

Percentage of hematoma evacuation identified by CT scan

次要结局

  • Linear measurement of accuracy(Day 0)
  • Functional Outcomes measured by modified Rankin Scale (mRS) for neurologic disabilities(Baseline, 3-month, 6-month and 1-year post-operative)

研究者

发起方
Zimmer Biomet
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验